Mayo Clinic | Strategic Alliance Partners

August 31, 2023

Lionel A. Kankeu Fonkoua, MD, discusses the importance of addressing barriers to clinical trial access that patients with cancer may face and increasing patient access to routine, primary care.

August 31, 2023

Mitesh J. Borad, MD, highlights key additional findings from ReFocus and how RLY-4008 differs from currently available FGFR2 inhibitors.

August 29, 2023

Lionel A. Kankeu Fonkoua, MD, discusses prevalent liver cancer clinical trial enrollment disparities.

August 25, 2023

Matthew P. Goetz, MD, discusses the available treatment options for patients with metastatic hormone receptor–positive breast cancer in the post-CDK inhibitor setting.

August 18, 2023

Lionel A. Kankeu Fonkoua, MD, discusses how the platinum chemotherapy shortage in the United States may exacerbate disparities in cancer care and the importance of conducting research to investigate the potential implications of this shortage on patients in underserved communities.

August 14, 2023

A panel of expert oncologists offer closing thoughts on the future treatment landscape and unmet needs in small-cell lung cancer.

August 09, 2023

Lionel A. Kankeu Fonkoua, MD, discusses challenges arising from the ongoing shortage of platinum chemotherapy in the United States and suggests potential alternatives to cisplatin that may benefit patients with cancer during this shortage.

August 07, 2023

Lionel Kankeu Fonkoua, MD, discusses the need for diverse representation across cancer clinical trials and research, emphasizes some of the disparities in enrollment criteria for these research efforts, and details some of the planned and ongoing initiatives at the Mayo Clinic that seek to facilitate change in the field.

August 07, 2023

Expert oncologists discuss important dosing considerations and treatment management strategies for lurbinectedin and other second-line therapy approaches in small-cell lung cancer.

August 07, 2023

Closing out their discussion on the management of relapsed/refractory diffuse large B-cell lymphoma, expert panelists highlight unmet needs and share excitement for future evolutions in the treatment landscape.

August 07, 2023

A review of the LAGOON and IMFORTE trials with expert insights regarding the potential clinical implications of current and future study findings.

July 31, 2023

Key opinion leaders reflect on data from the 2023 ASCO meeting and how it may impact the management of diffuse large B-cell lymphoma.

July 31, 2023

A panel of expert oncologists present the case of a 78-year-old woman who is treated with lurbinectedin following disease progress on first-line carboplatin, etoposide, and atezolizumab.

July 31, 2023

Panel experts discuss evolving treatment options for small-cell lung cancer in the second-line setting and beyond.

July 28, 2023

Tanios S. Bekaii-Saab, MD, offers closing thoughts on the unmet needs and future of HER2+ metastatic colorectal cancer treatment.

July 26, 2023

In this seventh episode of OncChats: Examining the Promise of Multicancer Early Detection Tests, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Niloy Jewel J. Samadder, MD, discuss the data that are still needed to inform optimal utilization of multicancer early detection tests and their potential cost effectiveness.

July 26, 2023

Findings from an analysis of treatment patterns for patients with systemic amyloid light chain amyloidosis have demonstrated that several unmet needs exist, including timely diagnosis and limited survival outcomes for patients with advanced disease.

July 26, 2023

Closing out their panel on metastatic colorectal cancer, expert oncologists consider ongoing challenges and future evolutions within the treatment landscape.

July 24, 2023

Faculty discuss real world data for treatment approaches using chemotherapy in combination with immunotherapy in extensive-stage small-cell lung cancer.

July 24, 2023

Expert oncologists present the case of a 45-year-old woman with synaptophysin-positive, extensive-stage small-cell lung cancer with a Ki-67 score of 90%, who is treated with carboplatin, etoposide, and atezolizumab in the first-line setting, and provide their initial impressions.